Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the development and commercialization of products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among othe
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
(Date:12/15/2014)... -- BerGenBio AS, a biopharmaceutical company focused ... today announces that it has raised NOK90 million (c. ... existing investors. BerGenBio will use the proceeds ... pipeline of innovative cancer therapeutics, in particular an enlarged ... a first-in-class selective Axl kinase inhibitor, which is currently ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... Anaphore Inc. today announced that the company ... Corporation (Osaka, Japan) for the research, development and commercialization ... The partnership will be based on ... called Atrimers(TM ) with binding domains that can ...
... MISSISSAUGA, Ontario, Dec. 13, 2010 Valeant Pharmaceuticals International, ... announced that Robert A. Ingram, Valeant,s lead independent director, ... replacing William M. Wells, who has resigned from the ... About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is ...
Cached Medicine Technology:Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... diseases, one worrisome phenomenon is when an illness that originated ... known as zoonosis -- is not uncommon and keeps researchers ... animal-borne disease might make inroads into the human population. ... and the culprits in this case were guinea pigs. More ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... health, but a growing body of evidence shows the ancient ... In fact, the benefits were similar to those of ... Chu, a doctoral candidate at Harvard University,s Health Policy Program ... that people randomly assigned to take yoga classes saw improvements ...
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... Steven Reinberg HealthDay Reporter ... new study should reassure the millions of American women who ... breast cancer. "There is no association between migraine and ... professor of medicine at Harvard Medical School. "There is no ... there is no protective effect either." About 18 percent ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... , THURSDAY, Jan. 20 (HealthDay News) -- Emotions can ... products such as airbags, vaccines and smoke detectors, researchers ... they learn that a safety product may carry certain ... airbags sometimes injure or kill. But just because these ...
... HealthDay Reporter , THURSDAY, Jan. 20 (HealthDay News) -- ... the help of aides Wednesday, bodes well for her ... will be moved Friday, just 13 days after a ... University Medical Center in Tucson indicate that the Arizona ...
... paper published Jan. 21 in the journal Science , ... Blossom Damania, PhD, has shown for the first time that ... a key molecule involved in the human immune response. ... Kenan, Jr. Distinguished Professor, Jenny Ting, PhD. First ...
... support system in the first year after diagnosis are less ... to new research from Vanderbilt-Ingram Cancer Center (VICC) and the ... author Meira Epplein, Ph.D., assistant professor of Medicine at VICC, ... of Clinical Oncology. Patients in the study ...
... have found that when patients and providers speak ... better health care quality. The findings were based ... Johnson Foundation,s Latino Health Survey. Understanding the ... important public health implications for providing services in ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... be behaving very differently depending on what side of ... example, H1N1 ("swine") flu still predominated in Britain, where 112 ... flu patients, and some doctors report running out of vaccine, ...
Cached Medicine News:Health News:Emotions May Sidetrack Use of Safety Devices 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 2Health News:Rep. Giffords Standing Up, Set to Begin Rehab Friday 3Health News:Viral protein mimic keeps immune system quiet 2Health News:Strong social ties benefit breast cancer patients 2Health News:Speaking the same language means better health care quality, Wayne State University study finds 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 2Health News:H1N1 Flu Is Raging in Britain; Could U.S. Be Next? 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: